DOPTELET
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DOPTELET (DOPTELET).
Avatrombopag is an orally bioavailable thrombopoietin receptor agonist that binds to and activates the thrombopoietin receptor (c-Mpl), stimulating megakaryocyte proliferation and differentiation, leading to increased platelet production.
| Metabolism | Avatrombopag is primarily metabolized by CYP2C9 and CYP3A4. |
| Excretion | Primarily fecal (biliary) elimination (87.9% of dose), with renal excretion accounting for 11.6%. |
| Half-life | Terminal elimination half-life is approximately 19 hours (range 11–35 h) after oral administration, supporting once-daily dosing. |
| Protein binding | >96% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Approximately 0.24 L/kg, indicating limited extravascular distribution in total body water. |
| Bioavailability | Oral bioavailability is approximately 19% (range 12–27%) due to first-pass metabolism. |
| Onset of Action | Oral: Onset of platelet count increase observed within 2–5 days after first dose. |
| Duration of Action | Platelet count elevation maintained during daily dosing; counts return to baseline within 7–10 days after discontinuation. |
Initial dose: 40 mg orally once daily for 5 days, starting 5 to 10 days before the scheduled procedure. For patients with any prior platelet transfusion or who are refractory to platelet transfusions: 60 mg orally once daily for 5 days.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment (eGFR ≥30 mL/min/1.73 m²). For severe renal impairment (eGFR 15-29 mL/min/1.73 m²): reduce dose to 40 mg orally once daily for 5 days. Not recommended in end-stage renal disease (eGFR <15 mL/min/1.73 m² or on dialysis). |
| Liver impairment | For Child-Pugh class A: no dose adjustment. For Child-Pugh class B: reduce dose to 40 mg orally once daily for 3 days. For Child-Pugh class C: not recommended. |
| Pediatric use | Safety and effectiveness in pediatric patients (<18 years) have not been established. No recommended dose. |
| Geriatric use | No specific dose adjustment recommended based on age alone. Consider renal function for dosing adjustments. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for DOPTELET (DOPTELET).
| Breastfeeding | It is unknown if avatrombopag is excreted in human milk. No M/P ratio has been determined. Because of the potential for serious adverse reactions in nursing infants (e.g., thrombocytosis), a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. |
| Teratogenic Risk | Teratogenic risk cannot be excluded. In animal studies, DOPTELET (avatrombopag) was not teratogenic in rats or rabbits at exposures up to 13 times the human AUC at the recommended human dose. No fetal harm is expected based on mechanism of action (TPO receptor agonist). However, limited human data in pregnancy are available; use only if clearly needed. |
■ FDA Black Box Warning
WARNING: THROMBOTIC/THROMBOEMBOLIC COMPLICATIONS. Avatrombopag increases the risk of thrombotic and thromboembolic events. Portal vein thrombosis has been reported in patients with chronic liver disease. Thrombotic events have been reported in patients with ITP. Use with caution in patients with known risk factors for thromboembolism, including genetic prothrombotic conditions.
| Serious Effects |
None known.
| Precautions | Thrombotic/thromboembolic complications; risk of progression of hematologic malignancies; risk of cataracts (observed in animal studies); use with caution in patients with hepatic impairment; drug interactions with CYP2C9 and CYP3A4 inhibitors/inducers. |
Loading safety data…
| Fetal Monitoring | Monitor platelet count weekly until stable, then monthly. Observe for signs of thrombosis. In pregnancy, standard prenatal monitoring is recommended; no specific fetal monitoring is required beyond routine obstetric care. |
| Fertility Effects | No specific human studies on fertility. Animal studies showed no effects on male or female fertility at exposures up to 6 times the human AUC. No known impairment of fertility clinically. |